Table 1. The association between NOD1+ CD68+ cell infiltration and clinicopathological characteristics in the HCC cohort.
HBsAg, hepatitis B surface antigen; AFP, α-fetoprotein; MVI, microvascular invasion; TNM, tumor-nodes-metastasis; BCLC, Barcelona Clinic Liver Cancer.
| Variable | NOD1+CD68+cell-low | NOD1+CD68+cell-high | P value |
|---|---|---|---|
| (n = 91) | (n = 34) | ||
| Age (years) | 0.810 | ||
| ≤65 | 74 (81.3%) | 27 (79.4%) | |
| >65 | 17 (18.7%) | 7 (20.6%) | |
| Gender | 0.809 | ||
| Male | 76 (83.5%) | 29 (85.3%) | |
| Female | 15 (16.5%) | 5 (14.7%) | |
| HbsAg | 0.138 | ||
| Negative | 18 (19.8%) | 11 (32.4%) | |
| Positive | 73 (80.2%) | 23 (67.6%) | |
| HCV | 0.618 | ||
| Negative | 89 (97.8%) | 33 (97.1%) | |
| Positive | 2 (2.2%) | 1 (2.9%) | |
| AFP (ng/ml) | 0.496 | ||
| ≤400 | 64 (70.3%) | 26 (76.5%) | |
| >400 | 27 (29.7%) | 8 (23.5%) | |
| Cirrhosis | 0.700 | ||
| Absent | 16 (17.6%) | 7 (20.6%) | |
| Present | 75 (82.4%) | 27 (79.4%) | |
| Ascites | 0.386 | ||
| Absent | 85 (93.4%) | 33 (97.1%) | |
| Present | 6 (6.6%) | 1 (2.9%) | |
| Tumor size (cm) | 0.545 | ||
| ≤5 | 59 (64.8%) | 24 (70.6%) | |
| >5 | 32 (35.2%) | 10 (29.4%) | |
| Tumor number | 0.021* | ||
| Single | 80 (87.9%) | 24 (70.6%) | |
| Multiple | 11 (12.1%) | 10 (29.4%) | |
| Tumor encapsulation | 0.286 | ||
| Absent | 81 (89.0%) | 33 (97.1%) | |
| Present | 10 (10.7%) | 1 (2.9%) | |
| Tumor differentiation | 0.177 | ||
| I and II | 58 (63.7%) | 26 (76.5%) | |
| III and IV | 33 (36.3%) | 8 (23.5%) | |
| MVI | 0.473 | ||
| Absent | 58 (63.7%) | 24 (70.6%) | |
| Present | 33 (36.3%) | 10 (29.4%) | |
| Vascular invasion | 0.256 | ||
| Absent | 80 (87.9%) | 32 (94.1%) | |
| Present | 11 (12.1%) | 2 (5.9%) | |
| TNM stage | 0.648 | ||
| I and II | 47 (51.6%) | 16 (47.1%) | |
| III and IV | 44 (48.4%) | 18 (52.9%) | |
| BCLC stage | 0.427 | ||
| 0 + A | 49 (53.8%) | 21 (61.8%) | |
| B + C | 42 (46.2%) | 13 (38.2%) |